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effusions
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OBJECTIVES: Our previous study demonstrated that superoxide dismutase levels were higher in tuberculous
pleural effusions than in malignant pleural effusions, but that this difference could not be used to discriminate
between the two. The objective of the present study was to investigate the levels of superoxide dismutase 2 in
pleural effusions and to evaluate the diagnostic significance of pleural effusion superoxide dismutase 2.
METHODS: Superoxide dismutase 2 concentrations were determined in pleural effusions from 54 patients with
tuberculous pleural effusion and 33 with malignant pleural effusion using an enzyme-linked immunosorbent
assay (ELISA) kit. Pleural effusion interferon gamma and tumor necrosis factor alpha levels were also analyzed
by ELISA. The Mann-Whitney U test was used to evaluate the significance of differences. Associations between
superoxide dismutase 2 concentrations and sex, age and smoking habits were assessed using Spearman’s or
Pearson’s correlation coefficient analysis. Receiver operator characteristic analysis was performed to evaluate
the value of superoxide dismutase 2 levels in the discrimination of tuberculous pleural effusion from malignant
pleural effusion.
RESULTS: Superoxide dismutase 2 levels were significantly higher in patients with tuberculous pleural effusion
compared with those with malignant pleural effusion (p,0.05). When superoxide dismutase 2 was used to
differentiate between tuberculous pleural effusions and malignant pleural effusions, the area under the
receiver operator characteristic curve was 0.909 (95% confidence interval, 0.827-0.960; p,0.01). With a cut-off
value of 54.2 ng/mL, the sensitivity, specificity, positive likelihood ratio and negative likelihood ratio were
75.8% (95%CI: 57.7-88.9%), 98.1% (95%CI: 90.1-99.7%), 40.91 and 0.25, respectively. Furthermore, significant
correlations between pleural effusion superoxide dismutase 2 and interferon gamma (r = 0.579, p,0.01) and
between pleural effusion superoxide dismutase 2 and tumor necrosis factor alpha (r = 0.396, p,0.01) were
observed.
CONCLUSION: Pleural effusion superoxide dismutase 2 can serve as a biomarker for differentiating between
tuberculous pleural effusions and malignant pleural effusions. Because of the high correlations of superoxide
dismutase 2 with pleural effusion interferon gamma and tumor necrosis factor alpha levels, this marker may act
as an inflammatory factor that plays an important role in the development of tuberculous pleural effusion.
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& INTRODUCTION
Over the past few years, a large volume of research has
been carried out on the redox state of Mycobacterium
tuberculosis (M.TB) infection and cancer. M.TB is continually
exposed to endogenous reactive oxygen species (ROS)
during normal aerobic respiration, as well as exogenous
ROS and reactive nitrogen species (RNS) generated by the
host immune system in response to infection. To avoid
oxidative damage, M.TB is equipped with various sophis-
ticated redox sensors that detect oxidative stress to maintain
redox homeostasis (1,2).
Oxidative stress is closely related to all aspects of cancer,
from carcinogenesis to the cancer-bearing state. Important
to carcinogenesis, the unregulated or prolonged production
of cellular oxidants has been linked to gene mutation and
the modification of gene expression and signal transduction
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pathways (3). The cancer-bearing state is also said to be
under oxidative stress associated with active oxygen
production by cancer cells and abnormal oxidation-reduc-
tion control, antioxidant enzyme over-expression and high
levels of the non-enzymatic antioxidant scavengers are key
components of cancer cell survival in an ROS-rich environ-
ment (4).
Superoxide dismutase (SOD) is an antioxidant enzyme
involved in the defense system against ROS. SOD catalyzes
the dismutation reaction of superoxide radical anion (O2
-) to
hydrogen peroxide, which is then catalyzed to innocuous O2
and H2O by glutathione peroxidase and catalase. An
imbalance in this coordinated system leads to increased
oxidative stress. When acclimating to increased levels of
oxidative stress, SOD concentrations typically increase with
increased in the magnitude in the stressful conditions. In
our previous studies (5), a significant difference in SOD
activity between tuberculous pleural effusions (TPEs) and
malignant pleural effusions (MPEs) was observed.
However, pleural effusion (PE) SOD levels were not an
accurate biomarker for differentiating between TPE and
MPE, exhibiting a sensitivity of 61.4% and specificity of
61.0%.
Three forms of SOD are present in humans, including
SOD1 (Cu/Zn-SOD), SOD2 (Mn-SOD) and SOD3 (extra-
cellular copper/zinc SOD) (6). Over the past few years, PE
SOD1 levels have been evaluated in patients with PE, and
the concentration of SOD1 in patients with TPE have been
reported to be close to those found in patients with MPE (7).
We also investigated PE SOD3 levels in patients with TPE
and MPE. Although SOD3 levels tended to be higher in the
TPE group, the difference was not significant (data not
published).
Based on the problems highlighted above, we performed
the present study to 1) determine the levels of SOD2 by
ELISA and 2) examine the diagnostic accuracy of SOD2 in
the differential diagnosis between TPE and MPE.
& METHODS
Study design and patients
This study was retrospectively conducted by the
Department of Lab Medicine, Shandong Provincial Chest
Hospital, Jinan City, Shandong Province. The study protocol
was approved by the Ethical Committee of the Shandong
Provincial Chest Hospital.
Between March and June 2013, patients with pleural
effusion were enrolled in this study and written informed
consent was obtained from all enrolled individuals.
Subsequently, the patients were included if the PE exam-
inations and/or pleural biopsy specimens established a
diagnosis of TPE or MPE. TPE was diagnosed by confirming
one of the following: isolation of M.TB from PE or pleural
tissue; pleural biopsy revealing granulomatous tissue with-
out any evidence of other granulomatous diseases; detection
of granulomas in the pleural tissue with a positive response
(a progressive reduction of symptoms, effusion removed
and radiologic improvement) to anti-TB treatment. MPE
was diagnosed if the cytology or pleural biopsy specimen
revealed an underlying malignancy.
Sample collection and analysis
PEs were collected within 24 h after hospitalization, before
any treatment had been initiated. PEs were centrifuged at
1200 r/min and 4 C˚ for 15 min and the supernatants were
immediately frozen in 1.5-mL Ep tubes and stored for three to
seven months at -80 C˚. The MB/BacT Alert 3D (MB/BacT)
system (Organon Teknika, Boxtel, The Netherlands) was
used to isolateM.TB. PE SOD2 levels were determined using
a commercially available enzyme-linked immunosorbent
assay kit (Abnova Taiwan Corporation, Taipei, Taiwan)
according to the manufacturers’ protocols. PE IFN-c and
TNF-a levels were also analyzed using ELISA kits
(Invitrogen, Camarillo, CA, USA).
Statistical analysis
Sample size estimation (power: 0.95, a= 0.05) was
performed using G*P 3.1.7 (8). Statistical analysis was
carried out using SPSS 17.0 software and MedCalc Version
8.0.1.0. Distributions were evaluated using the Kolmogorov-
Smirnov test for normality. Data were expressed as the
mean ¡ standard deviation (SD) if they were normally
distributed. Otherwise, median values were presented.
Significant differences between the means were calculated
using Student’s t-test if the population distribution was
normal; otherwise, the Mann-Whitney U test was used.
Associations between SOD2 concentrations and sex, age,
and smoking habits were assessed using Spearman’s or
Pearson’s correlation coefficient analysis. Receiver operator
characteristic (ROC) analysis was performed to evaluate the
sensitivity and specificity of SOD2; the cut-off point was
determined as the value of the parameter that maximized
the sum of the specificity and sensitivity. Positive and
negative likelihood ratios were also determined. A p-value
,0.05 was considered statistically significant.
& RESULTS
Patient characteristics
Of 421 patients with PE studied, 64 patients were excluded
after being diagnosed with other diseases (not TPE or MPE)
and 13 were excluded due to the presence of transudates
according to previously defined criteria (9). Another 257 of
the remaining 344 patients with PE were excluded because
they did not satisfy the criteria for definitive diagnosis.
Finally, 87 patients, 33 with malignant effusions and 54 with
tuberculous effusions (48 patients with positive cultures, 4
patients with granulomas excluding other granulomatous
diseases and 2 patients with granulomas and a positive
response to anti-TB treatment), were included in our study.
Table 1 presents the mean age, sex, smoking habits and other
characteristics of the evaluated patients. The study popula-
tion had a mean age of 43.07¡20.10 years (range: 15 to 87
years) and 65.5% of the patients were male. The mean age of
the 33 patients with MPE was 55.52 years (SD of 16.51 years)
and 70.0% of these patients were men. The mean age of the
patients with TPE was 35.46 years (SD of 18.32 years) and
63.0% were men. Significant differences were observed in the
smoking habits (pack-years) and age between patients with
TPE and those with MPE (all p,0.01). The severity of TPE
relative to smoking habits (0.00, interquartile range: 0.00-
2.500) was lower than that of MPE (2.00, interquartile ranges:
1.00-60.00). The levels of PE IFN-c and TNF-a in patients with
TPE (IFN-c: 1128.44 (413.51-1350.51) pg/L; TNF-a: 180.88
(120.93-336.71) pg/L) were higher than those in patients with
MPE (IFN-c: 5.60 (4.97-6.95) pg/L; TNF-a: 28.15 (12.65-65.02)
pg/L, all p,0.01). Spearman’s correlation analysis revealed
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significant correlations between SOD2 and IFN-c (r = 0.579,
p,0.01) and between SOD2 and TNF-a (r = 0.396, p,0.01).
SOD2 in TPEs and MPEs
The levels of SOD2 in the PEs of patients with TPE or
MPE are presented in Table 1. The median PE SOD2
concentration in patients with TPE was 73.5 ng/mL (inter-
quartile range: 64.7-82.9 ng/mL), compared with 42.1 ng/
mL (interquartile range: 34.4-56.9 ng/mL) in patients with
MPE. PE SOD2 levels were significantly higher in patients
with TPE compared with those with MPE (p,0.05)
(Figure 1). SOD2 levels in the TPE or MPE patients were
not correlated with age (all p.0.05) and were independent
of the sex and smoking habits (all p.0.05).
Diagnostic performance of SOD2 in the
differentiation between TPE and MPE
The ability of SOD2 to differentiate between TPEs and
MPEs was evaluated using receiver operating characteristic
curve analysis (Figure 2). When SOD2 was used to
differentiate TPEs from MPEs, the area under the curve
value was 0.909 (95% confidence interval [CI]: 0.827-0.960;
p,0.001). With a cut-off value of 54.2 ng/mL, the sensitiv-
ity, specificity, positive likelihood ratio and negative like-
lihood ratio were 75.8% (95%CI: 57.7-88.9%), 98.1% (95%CI:
90.1-99.7%), 40.91 and 0.25, respectively.
& DISCUSSION
In this study, we investigated the presence of SOD2 in
pleural effusions (PEs) and evaluated the diagnostic
significance of PE SOD2 in the differentiation between
TPEs and MPEs. PE SOD2 levels were significantly higher in
patients with TPE compared with those with MPE (p,0.05).
When SOD2 was used to differentiate TPEs from MPEs, the
area under the ROC curve was 0.909 (95%CI: 0.827-0.960).
With a cut-off value of 54.2 ng/mL, the sensitivity,
specificity, positive likelihood ratio and negative likelihood
ratio were 75.8% (95%CI: 57.7-88.9%), 98.1% (95%CI: 90.1-
99.7%), 40.91 and 0.25, respectively. Meanwhile, significant
correlations between PE SOD2 and IFN-c (r = 0.579) and
between PE SOD2 and TNF-a (r = 0.396) levels were
observed. These data demonstrate that PE SOD2 could
serve as a biomarker for differentiating TPEs from MPEs.
Because of the high correlations between SOD2 and PE IFN-
c and TNF-a levels, the inflammatory factor SOD2 may play
an important role in the development of TPE.
Pleural effusion is a diagnostic challenge for clinicians, as
it can arise from various causes. In developing countries,
TPE and MPE are the two most common types of pleural
effusion (PE) (10,11). However, differentiating between TPE
and MPE represents a critical problem. In our previous
studies (5), we have demonstrated a significant difference in
SOD activity between TPEs and MPEs, with significantly
higher SOD levels observed in TPEs compared with MPEs.
However, SOD activity in PE was not an accurate biomarker
for differentiating TPEs from MPEs. Identifying the SOD
isoform that contributes to the difference in SOD levels
between TPEs and MPEs is crucial to understand the
mechanism and improve the differential diagnostic value of
this marker. The present study represents the first demon-
stration that PE SOD2 levels were significantly higher in
patients with TPE compared with those with MPE. Our data
show that SOD2 levels in the pleural fluid could serve as a
Figure 1 - Comparison of pleural effusion SOD2 concentrations
between patients with TPE (n =54) and those with MPE (n=33).
The horizontal bar indicates the cut-off point (54.2 ng/mL).
Figure 2 - Receiver operating characteristic curve of SOD2 for the
differential diagnosis of TPEs and MPEs. The area under the
curve was 0.909 (95%CI: 0.827-0.960).
Table 1 - Characteristics of the patients.
TPE (54 patients) MPE (33 patients)
Age 35.46¡18.32 55.52¡16.51
Sex, % male 63.00% 70.00%
Smoking habit (pack-years) 0.00 (0.00-2.500) 2.00 (1.00-60.00)
SOD2 (ng/mL) 73.5 (64.7-82.9) 42.1 (34.4-56.9)
IFN-c (pg/L) 1128.44 (413.51-1350.51) 5.60 (4.97-6.95)
TNF-a (pg/L) 180.88 (120.93-336.71) 28.15 (12.65-65.02)
Data are presented as the medians (interquartile ranges); IFN-c: interferon gamma; TNF-a: tumor necrosis factor alpha.
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biomarker for differentiating TPEs from MPEs. Compared
with other pleural effusion biomarkers, such as IFN-c and
adenosine deaminase (data not shown), SOD2 could not be
used to accurately diagnose tuberculous pleural effusion
and had limited diagnostic value.
SOD catalyzes the dismutation of superoxide anion (O2
-)
to oxygen (O2) and hydrogen peroxide (H2O2). An imbal-
ance in this coordinated system will lead to increased
oxidative stress. Many studies have examined oxidative
stress during tuberculosis and lung cancer (the major cause
of MPE) (12-14). There are three distinct SOD isoforms
(SOD1, SOD2 and SOD3) found in humans (15). SOD1 is the
predominant SOD isoform in most cells and tissues,
accounting for 70-80% of the total cellular SOD activity.
SOD2 is a key mitochondrial antioxidant enzyme. More
than 90% of SOD3 is found in the interstitial space within
tissues and extracellular fluids; SOD3 accounts for the
majority of plasma SOD activity (16-18). We evaluated
SOD3 in PEs and found no significant difference in SOD3
levels in the pleural fluid of patients with TPE compared
with those with MPE (data not published). Another report
indicated that the concentration of SOD1 in patients with
TPE was similar to that in patients with MPE (7).
The results of this work demonstrated that SOD2 levels
were significantly increased in TPE patients. Due to their
role in cellular metabolism, mitochondria are the major sites
of ROS production. SOD2 is the only known superoxide
scavenger in the mitochondria and is therefore likely to be
important in the regulation of overall cellular ROS levels. By
controlling ROS, SOD2 plays an important protective role
against oxidative stress in lung tissue (19-22). Although ROS
represent the first line of defense against microbial invasion
and replication, the over-expression of ROS can cause
collateral tissue damage. ROS levels were significantly
higher in M.TB-infected macrophages compared with
normal macrophages. Host cells may increase SOD2
expression to decrease ROS production and avoid damage
(23-26). Thus, ROS levels are an important cause of
increased SOD2 in TPEs compared with MPEs.
Furthermore, SOD2 down-regulation has been reported in
a variety of cancer cells with diverse tissue origins and
forced overexpression of this enzyme in carcinoma cells
decreases their tumorigenicity. Mitochondria play an
important role in apoptosis and cellular proliferation and
SOD2 may also be directly involved in carcinogenesis by
protecting against mitochondrial damage. Significant corre-
lations between PE IFN-c and TNF-a levels and SOD2 levels
were observed in our study, implying that SOD2 might
serve as an inflammatory factor and play an important role
in the development of TPE. IFN-c and TNF-a are crucial Th-
1-type cytokines that control TB infection (27,28). IFN-c
stimulates the killing capacity of macrophages via the
induction of ROS production (29-32) and increased TNF-a
levels (33,34). Thus, SOD2 levels may increase to counteract
the overexpression of ROS induced by IFN-c and TB
infection.
The limitation of this study is its retrospective nature,
which might lead to selection bias and thus the inability to
interpret or generalize the results. Hence, a future approach
will be to analyze PE SOD2 levels in a prospective, larger
cohort of patients to validate the utility of SOD2 as a
candidate biomarker in differentiating TPEs from MPEs.
In conclusion, we have demonstrated that SOD2 levels
were increased in patients with TPEs compared with those
with MPEs. We further described, for the first time, that PE
SOD2 levels could be used to differentiate TPEs from MPEs.
The precise pathophysiological roles of SOD2 in TPE and
MPE require further investigation. Because of the high
correlations of SOD2 levels with IFN-c and TNF-a levels,
SOD2 may act as an inflammatory factor that plays an
important role in the development of TPE.
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